Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient StoryRead more →

Stage III Triple-Negative Breast Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of June 2026, Stephanie described being a 10-year survivor after Stage III BRCA1-positive triple-negative breast cancer, with remission shown after chemotherapy and no recurrence described.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient StoryRead more →

Stage II BRCA1 Breast Cancer: Joy's Survivor Story

Patient Info: Joy R., Female | Stage II

Biomarkers: BRCA1 mutation

As of June 2026, Joy had no evidence of disease after chemotherapy, double mastectomy, and hysterectomy for Stage II breast cancer with a BRCA1 mutation, and had moved from 3-month to 6-month oncology monitoring.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Sian's Survivor Story

Patient Info: Sian Bevans, Female, 50s | Stage II

Biomarkers: Triple-positive

Sian was 11 years past diagnosis, completed 10 years of maintenance medication in May 2025, and reported feeling more like herself; no recurrence was described.

Cleveland ClinicRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Erica's Survivor Story

Patient Info: Erica, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative

As of December 2025, Erica had Stage IA ER-positive/PR-positive/HER2-negative ILC removed with negative lymph nodes, completed 16 rounds of radiation, and was focused on survivorship and advocacy.

Lobular Breast Cancer AllianceRead more →

Stage II Triple-Negative Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Rancik, Female, Under 40 | Stage II

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Jennifer entered remission in October 2017 after Stage II triple-negative breast cancer treatment and, as of October 2025, reported doing great and being off medications except occasional Zometa.

City of HopeRead more →

Facing Triple-Negative Breast Cancer: Chance’s Story

Patient Info: Chance, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of February 2025, Chance described follow-up after Stage II BRCA1-associated triple-negative breast cancer and stated that she did not currently have cancer, while continuing close surveillance.

The Patient StoryRead more →

Stage IV HR-Positive Breast Cancer: Kate's Patient Story

Patient Info: Kate, Female, Under 40 | Stage IV

Biomarkers: HR-positive

Metastatic Site: lymph nodes near the lungs; chest wall and skin…

Kate was receiving chemotherapy for Stage IV hormone-positive breast cancer, with surgery and radiation discussed as planned next steps but not yet completed in the source.

The Patient StoryRead more →

Breast invasive lobular carcinoma metastatic to the endometrium: hysterectomy and hormone therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2 negative, PR/HER2 negative.

Metastatic Site: endometrium (endometrial polyp)

No signs of recurrence were reported 18 months after total hysterectomy with bilateral adnexectomy for endometrial metastasis from invasive lobular breast carcinoma, with scheduled follow-up every 3 to 6 months.

PubMed CentralRead more →

Invasive Lobular Carcinoma: Kristie's Survivor Story

Patient Info: Kristie, Female

As of August 2024, Kristie was focused on survivorship and advocacy after extensive ILC treatment that included 20 weeks of chemotherapy, 25 radiation treatments, 2 years on Verzenio, estrogen blockers, and 5 surgeries.

Lobular Breast Cancer AllianceRead more →

Stage I Invasive Lobular Carcinoma: Jessica's Patient Story

Patient Info: Jessica, Female, 40s | Stage I

Biomarkers: Myriad genetic testing negative; Oncotype DX score 19; RSClin recurrence risk 19%; isolated tumor cells around 1 sentinel lymph node without invasion

As of July 2024, Jessica had completed bilateral mastectomy for Stage IB ILC and was moving forward with radiation and long-term hormone suppression after chemotherapy was not recommended.

Lobular Breast Cancer AllianceRead more →

HR-positive HER2-negative metastatic breast cancer: bone metastases managed with sequential endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 90%+, PR 80%+, HER2-. CA 15-3 was tracked during treatment.

Metastatic Site: skull base; spine; sternum; ribs; left iliac bone;…

Metastatic HR-positive, HER2-negative breast cancer remained under active management; after earlier progression, palbociclib plus fulvestrant and zoledronic acid produced stable/remission findings on PET/CT at 3 months and again 1 year later, with continued 3-month follow-up recommended.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer: Chantal's Survivor Story

Patient Info: Chantal, Female, Under 40 | Stage II

Biomarkers: Triple-negative breast cancer; BRCA1 mutation

As of December 2023, Chantal reported that she did not currently have cancer, was followed by medical oncology every 3-4 months, and used Signatera testing because tumor markers were not reliable for her.

The Patient StoryRead more →

Stage II HR-Positive Invasive Lobular Carcinoma: Megan's Survivor Story

Patient Info: Megan Claire Chase, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2 not reported

As of July 2023, Megan-Claire was in survivorship after Stage II invasive lobular breast cancer, with clear early scans but significant long-term effects, surgical menopause, chronic pain, fatigue, chemo brain, and inability to tolerate recurrence-prevention medications.

The Patient StoryRead more →

Stage IV PIK3CA Breast Cancer: Abigail's Patient Story

Patient Info: Abigail, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer with PIK3CA mutation and germline ATM mutation; later PD-L1 somatic change reported. HER2 not stated.

Metastatic Site: Bone, including femurs, spine, and humeri; later liver

As of October 2022, Abigail was living with Stage IV hormone-positive metastatic breast cancer after years of treatment, bone-dominant disease that later involved the liver, targeted therapies, genomic testing, and advocacy around clinical trials and patient research participation.

The Patient StoryRead more →

Invasive Lobular Carcinoma: Susie's's Patient Story

Patient Info: Susie's daughter, Female, 40s

As of May 2021, Susie’s daughter was living after treatment for an 8 cm invasive lobular carcinoma and dealing with side effects from different endocrine therapies, while Susie became active in ILC advocacy and research support.

Lobular Breast Cancer AllianceRead more →

Stage IV Breast Cancer: Natalia's Patient Story

Patient Info: Natalia Padron, Female | Stage IV

Biomarkers: No hereditary breast-cancer mutation identified

Metastatic Site: pelvic organs; ovaries

As of November 2019, Natalia was living about 5 years after a terminal metastatic breast cancer diagnosis, using daily treatment/medications to help control the cancer and advocating for the metastatic breast cancer community.

YouTube (ES search)Read more →

Stage I Breast Cancer: Aura's Patient Story

Patient Info: Aura, Female, 40s | Stage I

Aura completed mastectomy, lymphadenectomy, hysterectomy, and chemotherapy for Stage I breast cancer and remained on hormone therapy, with ongoing concerns but no documented recurrence or progression.

Our Cancer StoriesRead more →

Stage II HR-Positive Breast Cancer: Cath's Survivor Story

Patient Info: Cath, Female, 60s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Cath was declared cancer-free in June 2024 after Stage II luminal A ER-positive/PR-positive/HER2-negative breast cancer treated with surgery, radiation, and hormone therapy, though she continued to manage long-term side effects and recurrence fear.

Our Cancer StoriesRead more →

Metastatic lobular breast cancer to gynecologic sites: disease-free after surgery and chemotherapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2/C-Erb-B2-negative

Metastatic Site: vagina, uterus, ovaries

After treatment of vaginal, uterine, and ovarian metastases from lobular breast cancer, she was free from disease 12 months after completion surgery.

PubMed CentralRead more →